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P U B L I S H E D B Y E L S E V I E R I N C .LettersIncidence of Metabolic
Risk Factors Among
Healthy Obese Adults
20-Year Follow-UpThere is growing evidence that obese adults without
metabolic risk factor clustering (the so-called “healthy
obese”) progress to unhealthy obesity over time (1).
However, the pathophysiological changes underlying
the long-term transition into an unhealthy obese state
have not been well characterized. To inform clinical
management of healthy obesity, we aimed to identifyFIGURE 1 Incidence of Metabolic Risk Factors Among Initially Healt
Over 20 Years (n ¼ 1,120)
Results are incidence ratios and 95% confidence intervals (CI) for havin
regression models with robust error variances. Models are adjusted for
cholesterol or triglycerides was observed between groups. Baseline hea
pertension, low high-density lipoprotein cholesterol, high triglycerides,the metabolic risk factors responsible for this transi-
tion, as well as the timing of their onset.
Repeat clinical data were drawn from the Whitehall
II cohort study of British adults. We grouped partici-
pants as normal-weight (body mass index [BMI] 18.5
to 24.9 kg/m2), overweight (BMI 25 to 29 kg/m2), or
obese (BMI $30 kg/m2), and as healthy (2) if they were
free of any the following characteristics: high-density
lipoprotein cholesterol <1.03 mmol/l (men) and <1.29
mmol/l (women); blood pressure $130/85 mm Hg or
antihypertension medication use; fasting plasma
glucose $5.6 mmol/l or diabetic medication use;
triglycerides $1.7 mmol/l; and homeostatic model–
assessed insulin resistance >2.83 (baseline 90th
percentile value). Participants provided writtenhy Obese Compared With Initially Healthy Normal-Weight Adults
g each metabolic risk factor at follow-up, on the basis of Poisson
age, sex, and ethnicity. Little difference in high-density lipoprotein
lthy status is defined as having none of 5 metabolic risk factors (hy-
insulin resistance, and high blood glucose).
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872informed consent. The University College London
research ethics committee provided ethical approval.
Cross-tabulations were used to describe incidence
of each of these 5 metabolic risk factors at 5- (1997 to
1999), 10- (2002 to 2004), 15- (2007 to 2009), and 20-
year (2012 to 2014) follow-ups for healthy normal-
weight, overweight, or obese participants at baseline
(1992 to 1994). Poisson regression models with robust
error variances were used to estimate age-, sex-, and
ethnicity-adjusted incidence ratios and 95% confi-
dence intervals for having each metabolic risk factor
at follow-up for healthy obese compared with healthy
normal-weight adults at baseline.
Among 2,878 adults with anthropometric and
metabolic risk factor data at each time point, 1,120
adults (39 to 61 years of age; 68% male) were free of all
metabolic risk factors at baseline. This initially healthy
status was progressively rarer among those in higher
BMI groups, representing 51.5%, 25.8%, and 13.4%
of normal-weight, overweight, and obese adults,
respectively. Of the healthy obese participants, 57.1%
had at least 1 metabolic risk factor at the 5-year follow-
up, with corresponding proportions being 64.3% at 10
years and 78.6% at 20 years. These proportions were
smaller (32.8%, 46.7%, and 60.3%) among initially
healthy normal-weight participants.
After 5 years (Figure 1), relative to initially healthy
normal-weight adults, initially healthy obese adults
were 4.40 times more likely to be insulin resistant,
3.35 times more likely to have high blood glucose,
and 1.92 times more likely to be hypertensive (all
p < 0.05). Incident insulin resistance remained higher
over all subsequent follow-ups among baseline
healthy obese compared with healthy normal-weight
adults. Case numbers were small for 20-year inci-
dence of low high-density lipoprotein cholesterol
(2 cases) and high triglycerides (3 cases) among
healthy obese adults, with little difference in risk
compared with healthy normal-weight adults over
time. Additional data are available on request.
The risk of developing insulin resistance, high
blood glucose, and hypertension was 2 to 5 times
higher among initially healthy obese adults com-
pared with their healthy normal-weight counterparts,
and these changes were evident after only 5 years of
follow-up. There was little difference in progression
to dyslipidemia. However, the key factor explaining
the long-term decline of healthy obesity was insulin
resistance, which was consistently most common
among healthy obese adults over time.
Healthy obese adults are known to experience
an elevated future risk of type 2 diabetes (3) and
cardiovascular disease (4) compared with healthy
normal-weight counterparts. That insulin resistanceis an established indicator of future impaired glucose
metabolism (5) may explain their much higher inci-
dence of type 2 diabetes (relative risk near 4.0) (3) and
slightly higher incidence of cardiovascular disease
(relative risk near 1.2) (4), given that earlier onset of
risk factors leads to a greater cumulated exposure and
higher disease risk. Overall, our findings suggest that
healthy obesity is strongly linked with future insulin
resistance that subsequently induces cardiometabolic
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